As of 2026-03-30, the EV/EBITDA ratio of Mersana Therapeutics Inc (MRSN) is -1.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRSN's latest enterprise value is 89.01 mil USD. MRSN's TTM EBITDA according to its financial statements is -66.29 mil USD. Dividing these 2 quantities gives us the above MRSN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 14.9x | 14.0x |
| Forward P/E multiples | 15.1x - 20.1x | 17.8x |
| Fair Price | (188.92) - (186.27) | (199.19) |
| Upside | -749.6% - -740.5% | -785.0% |
| Date | EV/EBITDA |
| 2026-01-05 | -1.34 |
| 2026-01-02 | -1.34 |
| 2025-12-31 | -1.33 |
| 2025-12-30 | -1.31 |